A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive Disorder
Status:
Completed
Trial end date:
2017-11-08
Target enrollment:
Participant gender:
Summary
This is a two-part (open-label followed by double-blind) study evaluating the safety,
tolerability, pharmacokinetics, and efficacy of SAGE-217 in 102 participants diagnosed with
moderate to severe Major Depressive Disorder.